*To the Editor*:

We read with interest the insightful opinion provided by Nett and colleagues regarding the importance of gathering occupational and environmental exposure data within registries of patients with idiopathic pulmonary fibrosis (IPF) ([@bib1]). We agree with the authors that the collection of relevant exposure history data is crucial for understanding the pathophysiology of IPF and enriches patient registry data, as summarized by Culver and colleagues ([@bib2]). Furthermore, capturing detailed exposure data aligns with a recent American Thoracic Society and European Respiratory Society statement, which noted that up to 26% of IPF cases are potentially attributable to occupational and environmental exposures, including vapors, silica, and agricultural and metal dusts ([@bib3]). In recognition of this, participants in the Australian IPF Registry (AIPFR) complete a comprehensive occupation and exposure questionnaire at baseline, giving investigators the opportunity to explore the potential contribution of these factors to the development of IPF.

The AIPFR was established in 2011 as a platform for national and international collaborative research, and to provide multifaceted insights into IPF in Australia ([@bib4]). Participants are followed prospectively and data are collected at baseline and every 6 months. Similar to other registries, clinical data, including smoking history, family history, medication history, and relevant associated comorbidities (e.g., gastroesophageal reflux disease), are collated within the registry. In addition, as suggested by Nett and colleagues, the AIPFR collects detailed demographic, environmental, and occupational exposure data in the form of a questionnaire completed upon enrollment in the registry. Such data have provided researchers with a number of opportunities, such as an ongoing study that is exploring ambient air quality in various geographical locations across Australia with regard to its impact on patients with IPF. In addition, the AIPFR has collaborations with relevant government bodies studying the health economic impact of IPF with and without antifibrotic treatment, within which the impact of environmental exposures will also be considered. Finally, the AIPFR is linked to a national blood biobank, allowing interactions among genetic, demographic, and environmental influences to be explored.

We agree with Nett and colleagues' suggestion that a collaborative effort across registries in capturing and pooling occupational and environmental exposure data together is critical. The AIPFR's comprehensive approach provides a ready platform for international collaborations to occur. Although registries are useful for providing "real-world" data regarding a heterogeneous population, their limitations need to be acknowledged. Incomplete data entry is a recurring issue and tight quality control is required to minimize errors. However, other challenges, such as patient recall bias in establishing the time latency between multiple occupational or environmental exposures, development of symptoms, and time of diagnosis, are more difficult to address ([@bib5]). Although validated job exposure matrices are available ([@bib6]), their uptake remains variable from one country to another, and further efforts to standardize their usage are very much needed. We encourage continued discussions and collaboration among relevant parties in developing a standardized method and format that can be used globally to collect exposure data, which may contribute to future novel research in IPF.
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